Lipoxin agonists: turn right! to path of resolving neutrophil

Devchand, Pallavi R.

doi:10.1590/s0074-02762005000900010

Cited by 2 publications

(1 citation statement)

References 14 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, advances and increasing understanding of mechanisms underlying NSAID‐induced gastroduodenal damage have led to the development of potential newer therapeutics, including coxibs, COX and LOX dual‐inhibiting NSAIDs, NO‐NSAID, H 2 S‐NSAIDs, zinc‐NSAIDs, PC‐NSAIDs and zinc compounds. Optimism in this field is exuberantly reflected by such running titles from researchers as: ‘Building a better aspirin; gaseous solution to a century‐old problem’, 56 ‘Turn to the path of resolving neutrophil’, 96 ‘NO‐donating NSAIDs and cancer: An overview with a note on whether NO is required for their action’ 97 . In our opinion, it is likely that clinicians will be able to rescue their patients from the assault of NSAID damage in the near future.…”

Section: Perspective and Future Directionsmentioning

confidence: 99%

Rescue strategies against non‐steroidal anti‐inflammatory drug‐induced gastroduodenal damage

Lim

Lee

et al. 2009

J of Gastro and Hepatol

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly prescribed drugs worldwide, which attests to their efficacy as analgesic, antipyretic and anti-inflammatory agents as well as anticancer drugs. However, NSAID use also carries a risk of major gastroduodenal events, including symptomatic ulcers and their serious complications that can lead to fatal outcomes. The development of "coxibs" (selective cyclooxygenase-2 [COX-2] inhibitors) offered similar efficacy with reduced toxicity, but this promise of gastroduodenal safety has only partially been fulfilled, and is now dented with associated risks of cardiovascular or intestinal complications. Recent advances in basic science and biotechnology have given insights into molecular mechanisms of NSAID-induced gastroduodenal damage beyond COX-2 inhibition. The emergence of newer kinds of NSAIDs should alleviate gastroduodenal toxicity without compromising innate drug efficacy. In this review, novel strategies for avoiding NSAID-associated gastroduodenal damage will be described.

show abstract

Section: Perspective and Future Directionsmentioning

confidence: 99%